News & Events about Ikena Oncology Inc.
Ticker Report
2 months ago
Ikena Oncology (NASDAQ:IKNA Get Rating) had its price objective lowered by investment analysts at HC Wainwright from $26.00 to $22.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock. Separately, Credit ...
Ikena Oncology (NASDAQ:IKNA Get Rating) had its price objective lowered by investment analysts at HC Wainwright from $26.00 to $22.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock. Separately, Credit Suisse Group reduced ...
Globe Newswire
2 months ago
Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as planned in dose escalation; clinical data in 2023 Company prioritizes advancement of targeted oncology portfolio; cash runway extended into 2025 BOSTON, ...
Globe Newswire
2 months ago
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in 1x1 investor meetings at the Piper ...
Ticker Report
2 months ago
Ikena Oncology, Inc. (NASDAQ:IKNA Get Rating) Equities research analysts at William Blair decreased their Q4 2022 EPS estimates for Ikena Oncology in a research note issued on Tuesday, November 8th. William Blair analyst M. Phipps now anticipates that the company will post earnings ...